First Human Dosing of Gerilimzumab

RuiYi initiates clinical trial for autoimmune disorders drug

25-Sep-2015 - Netherlands

arGEN-X reports that its partner RuiYi, Inc., has announced the first human dosing of Gerilimzumab, a novel monoclonal antibody neutralizing the IL-6 cytokine, for the treatment of autoimmune disorders including rheumatoid arthritis.

arGEN-X licensed the worldwide rights to develop and commercialize Gerilimzumab to RuiYi in late 2012. Gerilimzumab was originally generated by arGEN-X using its SIMPLE Antibody™ platform and has been further differentiated with NHance®, its novel, proprietary technology, which prolongs the circulation time and improves tissue distribution of antibodies.

The clinical trial initiated by RuiYi is a double-blind, placebo controlled study in healthy volunteers, with both single and multiple ascending dose protocols. The start of the trial triggers an undisclosed milestone payment by RuiYi to arGEN-X.

Positive results from this study will support advancing Gerilimzumab into trials in patients with autoimmune disorders, including moderate to severe rheumatoid arthritis in 2016.

Other news from the department research and development

More news from our other portals

All FT-IR spectrometer manufacturers at a glance